Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580764 | 0.88 | UHRF1 (0.41) | NNMT | |
| SCHEMBL795352 | 0.75 | NNMT (0.44) | NNMTDRD1 | |
| SCHEMBL13991574 | 0.75 | PARP10 (0.42) | NNMTDRD1NOTUMGRM5 | |
| SCHEMBL13138806 | 0.75 | PARP1 (0.42) | NNMTDRD1NOTUM | |
| SCHEMBL10279840 | 0.75 | NNMT (0.37) | NNMTDRD1NOTUMGRM5 | |
| SCHEMBL10150102 | 0.75 | NOTUM (0.47) | NNMTDRD1NOTUM | |
| SCHEMBL22940330 | 0.75 | CRBN (0.36) | — | |
| SCHEMBL24288319 | 0.72 | NNMT (0.38) | NNMTDRD1 | |
| SCHEMBL14510804 | 0.72 | HTR2A (0.35) | NNMTGRM5 | |
| SCHEMBL21323893 | 0.71 | HTR2A (0.43) | NNMTDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242961-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-1984353-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2015-12-30 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2418209-B1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2014-03-06 | — | — | US | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| EP-2418209-A1 | Aurora kinase modulators and method of use | Amgen Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AMGEN INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-7560551-B2 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AMGEN INC. (US) | 2009-06-25 | — | — | US | disclosed |
| CN-101405282-A | Aurora kinase modulators and methods of use | AMGEN INC (US) | 2009-04-08 | — | — | CN | disclosed |
| EP-1984353-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | Amgen, Inc (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007087276-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AMGEN INC. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066430-A1 | AURORA KINASE MODULATORS AND METHOD OF USE | AURKC, AURKA, AURKB | NNMT 3336/4885DRD1 4469/4885NOTUM 4057/4885 |
| US-20070185111-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, CDK1 | NNMT 3099/4885DRD1 4722/4885NOTUM 4140/4885 |
| US-20110263530-A1 | Aurora Kinase Modulators and Method of Use | AURKC, AURKA, AURKB | NNMT 3336/4885DRD1 4469/4885NOTUM 4057/4885 |
| US-20090163501-A1 | Aurora kinase modulators and method of use | AURKC, AURKA, AURKB | NNMT 3336/4885DRD1 4469/4885NOTUM 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.